Physician profile
Marc Eric Jaffe
NPI 1043254725
$5,961.42
in general payments reported to CMS, 2019-2025
26 companies · $817 in 2025
The $817 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $497 · 2021: $1,125 · 2022: $862 · 2023: $1,050 · 2024: $779 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,645.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,103.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $900.15 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $806.62 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $560.45 | 2019-2024 | Jardiance |
| Amgen INC. | $391.35 | 2021-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $375.99 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $321.47 | 2019-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $246.63 | 2019-2025 | Belsomra, Steglatro, Lagevrio |
| Abbvie INC. | $217.18 | 2022-2025 | |
| Amarin Pharma, INC. | $196.85 | 2019-2021 | |
| Pfizer INC. | $158.92 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $103.43 | 2019-2021 | |
| Astellas Pharma US INC | $86.21 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $71.06 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $64.61 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $57.71 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.99 | 2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $43.54 | 2022-2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $36.40 | 2021 | |
| Ardelyx, INC. | $35.21 | 2025 | Ibsrela |
| Eisai INC. | $34.47 | 2021 | |
| Phathom Pharmaceuticals, INC. | $30.81 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $24.04 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.40 | 2021 | |
| Almatica Pharma LLC | $16.87 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.